T1000	Negation 2106 2109	not
E1000	Negation:T1000 Scope:T1001
T1001	Span 2106 2132	not CD3epsilon (P = 0.131)
T1002	Speculation 716 724	possible
E1001	Speculation:T1002 Scope:T1003
T1003	Span 716 796	possible correlation with clinical variables such as stage in selected instances
T1004	Negation 2692 2695	not
E1002	Negation:T1004 Scope:T1005
T1005	Span 2688 2749	was not accounted for by the advanced age of the study cohort
T1006	Negation 2509 2512	not
E1003	Negation:T1006 Scope:T1007
T1007	Span 2509 2518	not found
T1008	Negation 3118 3121	not
E1004	Negation:T1008 Scope:T1009
T1009	Span 3118 3131	not inducible
T1010	Negation 2973 2976	not
E1005	Negation:T1010 Scope:T1011
T1011	Span 2936 3027	impaired activation of NFkappaB does not appear linked to a reduction of TCRzeta expression
T1012	Speculation 3435 3438	may
E1006	Speculation:T1012 Scope:T1013
T1013	Span 3435 3498	may also revert to normal during IL-2/IFN alpha-based treatment
T1014	Speculation 3319 3322	may
E1007	Speculation:T1014 Scope:T1015
T1015	Span 3319 3361	may increase during cytokine-based therapy
T1016	Speculation 3679 3686	unclear
E1008	Speculation:T1016 Scope:T1017
T1017	Span 3627 3686	The clinical significance of these findings remains unclear
